The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Open accessAbstract
BACKGROUND: A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population. METHODS: We compared the incidence of CHD (myocardial infarction, fatal CHD, or coronary revascularization) over a 15-year interval in the Atherosclerosis Risk in Communities study according to the presence or absence of sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol. RESULTS: Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03). Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol and a 47 percent reduction in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003). CONCLUSIONS: These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes degradation of LDL receptors, thereby diminishing the clearance of LDL from the circulation. 6”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2005, a causative association was established between the presence of loss-of-function mutations in PCSK9 and lifelong reductions in LDL-C associated with lower CHD risk (3).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic studies have shown that carriage of PCSK9 loss-of-function alleles is associated with lower LDL cholesterol levels and a reduced risk of myocardial infarction.7,8”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that drugs that ultimately reduce LDL-C level predominantly through upregulation of LDL receptor expression should, barring any off-target adverse effects, lead to clinical benefit in proportion to the degree of LDL-C reduction.64”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike gain-of-function PCSK9 variants (7), loss-of-function (LOF) variants enhance LDLR levels and promote LDLc clearance (4, 8).”
From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Whereas PCSK9 loss-of-function mutations carriers with lifelong reductions in LDL-C and coronary heart disease incidence, were not initially found at significantly reduced risk of stroke (3, 72), a much larger study of the UK Biobank database described the first genetic evidence of a protective effect of the R46L loss-of-function mutation on PCSK9 on ischemic stroke (73).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
In the citing paper
“and that lowering LDL-C reduces the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C [2,51].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“The remarkable consistency among these studies, in addition to biological and experimental evidence, provides compelling evidence that LDL-C is causally associated with the risk of ASCVD”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“Both studies had relatively short follow-up periods and the evidence from statin trials indicates that the clinical benefits of LDL-lowering may only emerge after about 1 year [51], so these trials may have underestimated the potential impact of longer-term treatment [120,290].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“These developments have enabled researchers to bridge the gap between the monogenic and polygenic realms, identifying common variant modifiers of monogenic phenotypes contributing to the variable expression of rare, large-effect alleles26,93, and low-frequency and rare variants that influence common multifactorial traits94,95.”
From A brief history of human disease genetics (2020) · cites this paper as [95]
In the citing paper
“At the same time, it has become increasingly evident now that not only the magnitude of LDL-C lowering is important but that the duration of exposure to elevated LDL-C levels is equally important [11,16,38].”
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“The exceptionally low rates of CV events observed in patients carrying mutations in PCSK9 or other similar genes despite only modestly low LDL-C levels strongly support this notion [11].”
In the citing paper
“Hobbs and Cohen sequenced the gene (126, 127) and identified low-frequency common variants (0.5 to 1%), which allowed epidemiological research documenting a protective effect on myocardial infarction (128).”
From Genetic Mapping in Human Disease (2008) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
(1989) · PubMed · Cited by 3,139
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Self-citationSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
CORONARY DISEASE AMONG UNITED STATES SOLDIERS KILLED IN ACTION IN KOREA
Enos, W. F. (1953) · JAMA · doi:10.1001/jama.1953.03690120006002 · Cited by 891
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,025
Lipid lowering with PCSK9 inhibitors
Dadu, R. T., & Ballantyne, C. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.84 · Cited by 234
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
Ballantyne, C. M., Banka, P., Méndez, G., Garcia, R., Rosenstock, J., Rodgers, A., Mendizabal, G., Mitchel, Y., & Catapano, A. L. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.018 · Cited by 234
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D., Crispino, C., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 233
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
A new method for measurement of total plasma PCSK9: clinical applications
Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J. J., Bernier, L., Seidah, N. G., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900273-jlr200 · Cited by 231
Deep resequencing reveals excess rare recent variants consistent with explosive population growth
Coventry, A., Bull–Otterson, L., Liu, X., Clark, A. G., Maxwell, T. J., Crosby, J. R., Hixson, J. E., Rea, T. J., Muzny, D. M., Lewis, L. R., et al. (2010) · Nature Communications · doi:10.1038/ncomms1130 · Cited by 229
Self-citationGenetics of coronary artery disease and myocardial infarction
Dai, X. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i1.1 · Cited by 230
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
Zaman, S. J., Wasfy, J. H., Kapil, V., Ziaeian, B., Parsonage, W. A., Sriswasdi, S., Chico, T., Capodanno, D., Colleran, R., Sutton, N. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00055-8 · Cited by 236
Gaziano, L., Giambartolomei, C., Pereira, A. C., Gaulton, A., Posner, D. C., Swanson, S. A., Ho, Y.-L. A., Iyengar, S. K., Kosik, N., Vujković, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01310-z · Cited by 231
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 229
Ference, B. A., Bhatt, D. L., Catapano, A. L., Packard, C. J., Graham, I. M., Kaptoge, S. K., Ference, T. B., Guo, Q., Laufs, U., Ruff, C. T., et al. (2019) · JAMA · doi:10.1001/jama.2019.14120 · Cited by 228
Menopausal hormone therapy and women’s health: An umbrella review
Zhang, G.-Q., Chen, J.-L., Luo, Y., Mathur, M. B., Anagnostis, P. G., Nurmatov, U. B., Talibov, M., Zhang, J., Hawrylowicz, C. M., Lumsden, M. A., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003731 · Cited by 228
Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008144 · Cited by 227
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Surdo, P. L., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., & Carfí, A. (2011) · The EMBO Reports · doi:10.1038/embor.2011.205 · Cited by 226
Ding, Z., Liu, S., Wang, X., Deng, X., Fan, Y., Sun, C., Wang, Y., & Mehta, J. L. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6054 · Cited by 226
Leander, K., Mälarstig, A., Hooft, F. M. V., Hyde, C., Hellénius, M.-L., Troutt, J. S., Konrad, R. J., Öhrvik, J., Hamsten, A., & Fairé, U. D. (2016) · Circulation · doi:10.1161/circulationaha.115.018531 · Cited by 225
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
Denny, J. C., Bastarache, L. A., & Roden, D. M. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-024956 · Cited by 224
Chadwick, A. C., Wang, X., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309881 · Cited by 223
Demers, A., Samami, S., Lauzier, B., Des Rosiers, C., Sock, E. T. N., Ong, H., & Mayer, G. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306032 · Cited by 221
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D., Zheng, X., & Tang, C. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 222
Hemingway, H., Asselbergs, F. W., Danesh, J., Dobson, R., Maniadakis, N., Maggioni, A. P., van Thiel, G. J. M. W., Cronin, M., Brobert, G., Vardas, P. E., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx487 · Cited by 218
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
In utero CRISPR-mediated therapeutic editing of metabolic genes
Rossidis, A. C., Stratigis, J. D., Chadwick, A. C., Hartman, H. A., Ahn, N. J., Li, H., Singh, K., Coons, B. E., Li, L., Lv, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0184-6 · Cited by 216
Karatasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215
Baass, A. W., Dubuc, G., Tremblay, M., DELVIN, E. E., O’Loughlin, J. L., Levy, E. H., Davignon, J., & Lambert, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.126987 · Cited by 213
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah, N. G., & Prat, A. (2012) · Circulation · doi:10.1161/circulationaha.111.057406 · Cited by 212
Mendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 211
Da Dalt, L., Ruscica, M., Bonacina, F., Balzarotti, G., Dhyani, A., Di Cairano, E., Baragetti, A., Arnaboldi, L., De Metrio, S., Pellegatta, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy357 · Cited by 209
Thanassoulis, G., & O’Donnell, C. J. (2009) · JAMA · doi:10.1001/jama.2009.812 · Cited by 209
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening
Singh, S., & Bittner, V. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0482-5 · Cited by 206
Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease
Arnett, D. K., Baird, A. E., Barkley, R. A., Basson, C. T., Boerwinkle, E., Ganesh, S. K., Herrington, D. M., Hong, Y., Jaquish, C. E., McDermott, D. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.183679 · Cited by 205
Self-citationLowering LDL—not only how low, but how long?
Brown, M. S., & Goldstein, J. L. (2006) · Science · doi:10.1126/science.1125884 · Cited by 204
Kühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
A federated ecosystem for sharing genomic, clinical data
The Global Alliance for Genomics and Health* (2016) · Science · doi:10.1126/science.aaf6162 · Cited by 204
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 203
Recognition and Management of Dyslipidemia in Children and Adolescents
Kwiterovich, P. O. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1270 · Cited by 203
Familial hypercholesterolemia treatments: Guidelines and new therapies
Raal, F. J., Hovingh, G. K., & Catapano, A. L. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.859 · Cited by 203
Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction
Ridker, P. M., Paré, G., Parker, A. N., Zee, R. Y. L., Miletich, J. P., & Chasman, D. I. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.817304 · Cited by 202
Wahane, A. V., Waghmode, A., Kapphahn, A., Dhuri, K., Gupta, A., & Bahal, R. (2020) · Molecules · doi:10.3390/molecules25122866 · Cited by 202
Molecular basis of PCSK9 function
Lambert, G. C., Charlton, F., Rye, K., & Piper, D. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.010 · Cited by 201
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, R. P., & Sabatine, M. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.001 · Cited by 200
Detection and Treatment of Vulnerable Plaques and Vulnerable Patients
Waxman, S., Ishibashi, F., & Muller, J. E. (2006) · Circulation · doi:10.1161/circulationaha.105.540013 · Cited by 199
Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus
Maahs, D. M., Daniels, S. R., de Ferranti, S. D., Dichek, H. L., Flynn, J. T., Goldstein, B. I., Kelly, A. S., Nadeau, K. J., Martyn-Nemeth, P. A., Osganian, S. K., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000094 · Cited by 199
Extending genome-wide association studies to copy-number variation
McCarroll, S. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn282 · Cited by 197
Davis, J. R., Wang, X., Witte, I. P., Huang, T. P., Levy, J. M., Raguram, A., Banskota, S., Seidah, N. G., Musunuru, K., & Liu, D. R. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00911-4 · Cited by 199
The LDL cumulative exposure hypothesis: evidence and practical applications
Ference, B. A., Braunwald, E., & Catapano, A. L. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01039-5 · Cited by 196
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Qian, Y.-W., Schmidt, R. J., Zhang, Y., Chu, S., Lin, A., Wang, H., Wang, X., Beyer, T. P., Bensch, W. R., Li, W., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700071-jlr200 · Cited by 194
Gene-centric Association Signals for Lipids and Apolipoproteins Identified via the HumanCVD BeadChip
Talmud, P. J., Drenos, F., Shah, S. H., Shah, T., Palmen, J., Verzilli, C. J., Gaunt, T. R., Pallas, J. A., Lovering, R. C., Li, K., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.10.014 · Cited by 194
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans
Edmondson, A. C., Brown, R., Kathiresan, S., Cupples, L. A., Demissie, S., Manning, A. K., Jensen, M. K., Rimm, E. B., Wang, J., Rodrigues, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37176 · Cited by 194
Prevention of atherosclerosis from childhood
Raitakari, O. T., Pahkala, K., & Magnussen, C. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00647-9 · Cited by 197
Proprotein Convertases in Health and Disease
Artenstein, A. W., & Opal, S. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1106700 · Cited by 193
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Wu, C.-Y., Tang, Z.-H., Jiang, L., Li, X.-F., Jiang, Z.-S., & Liu, L.-S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1028-6 · Cited by 190
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
Cheng, J. M., Oemrawsingh, R. M., García‐García, H. M., Boersma, E. H., van Geuns, R., Serruys, P. W. J. C., Kardys, I., & Akkerhuis, K. M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.010 · Cited by 190
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
Santos, R. D., Ruzza, A., Hovingh, G. K., Wiegman, A., Mach, F., Kurtz, C. E., Hamer, A. W., Bridges, I. M., Bartuli, A., Bergeron, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019910 · Cited by 190
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189
Self-citationMaki, K. C., Beiseigel, J. M., Jonnalagadda, S. S., Gugger, C. K., Reeves, M. S., Farmer, M. V., Kaden, V. N., & Rains, T. M. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2009.10.037 · Cited by 188
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Gersh, B. J. (2007) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)70160-6 · Cited by 188
Gaba, P., O’Donoghue, M. L., Park, J., Wiviott, S. D., Atar, D., Kuder, J., Im, K., Murphy, S. A., Ferrari, G. M. D., Gaciong, Z. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063399 · Cited by 188
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Stroke genetics: discovery, biology, and clinical applications
Dichgans, M., Pulit, S. L., & Rosand, J. M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30043-2 · Cited by 187
Evaluating drug targets through human loss-of-function genetic variation
Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2267-z · Cited by 188
Kao, W. H. L., Arking, D. E., Post, W. S., Rea, T. D., Sotoodehnia, N., Prineas, R. J., Bishé, B., Doan, B. Q., Boerwinkle, E., Psaty, B. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.791723 · Cited by 184
Self-citationA PCSK9 Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
Kathiresan, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707445 · Cited by 183
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Grefhorst, A., McNutt, M. C., Lagace, T. A., & Horton, J. D. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800027-jlr200 · Cited by 183
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Fisher, T. S., Surdo, P. L., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701634200 · Cited by 181
Intermediate phenotypes in psychiatric disorders
Rasetti, R., & Weinberger, D. R. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.02.003 · Cited by 181
RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors
Thakore, P. I., Kwon, J. B., Nelson, C. E., Rouse, D. C., Gemberling, M. P., Oliver, M. L., & Gersbach, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04048-4 · Cited by 181
Sex differences in lipids: a life course approach
Holven, K. B., & Roeters van Lennep, J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117270 · Cited by 180
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180
The Severe Hypercholesterolemia Phenotype
Sniderman, A. D., Tsimikas, S., & Fazio, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.060 · Cited by 180
Kessler, T., Vilne, B., & Schunkert, H. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506174 · Cited by 180
PCSK9 Biology and Its Role in Atherothrombosis
Barale, C., Melchionda, E., Morotti, A., & Russo, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115880 · Cited by 180
Molecular diagnosis of hypobetalipoproteinemia: An ENID review
Tarugi, P., Averna, M. R., Leo, E. D., Cefalu, A. B., Noto, D., Magnolo, L., Cattin, L., Bertolini, S., & Calandra, S. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.003 · Cited by 179
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178
Tavori, H., Fan, D., Blakemore, J. L., Yancey, P. G., Ding, L., Linton, M. F., & Fazio, S. (2013) · Circulation · doi:10.1161/circulationaha.113.001592 · Cited by 178
Hypobetalipoproteinemia and abetalipoproteinemia
Welty, F. K. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000072 · Cited by 177
Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176
Metabolic analysis as a driver for discovery, diagnosis, and therapy
DeBerardinis, R. J., & Keshari, K. R. (2022) · Cell · doi:10.1016/j.cell.2022.06.029 · Cited by 177
Gupta, N., Fisker, N., Asselin, M.-C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., & Straarup, E. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010682 · Cited by 174
Non-cardiovascular effects associated with statins
Desai, C. S., Martin, S. S., & Blumenthal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3743 · Cited by 174
Halpern, A., Mancini, M. C., Magalhães, M. E. C., Fisberg, M., Radominski, R. B., Bertolami, M. C., Bertolami, A., de Melo, M. E., Zanella, M. T., Queiroz, M. S., et al. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-55 · Cited by 172
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Ballantyne, C. M., Neutel, J., Cropp, A., Duggan, W. T., Wang, E. Q., Plowchalk, D. R., Sweeney, K., Kaila, N., Vincent, J., & Bays, H. E. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.02.006 · Cited by 171
Genetic susceptibility to myocardial infarction and coronary artery disease
Topol, E. J., Smith, J., Plow, E. F., & Wang, Q. K. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl183 · Cited by 171
May, C. L., Kourimate, S., Langhi, C., Chétiveaux, M., Jarry, A., Coméra, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181586 · Cited by 171
The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion
Gustafsen, C., Kjolby, M., Nyegaard, M., Mattheisen, M., Lundhede, J., Buttenschøn, H., Mors, O., Bentzon, J. F., Madsen, P., Nykjaer, A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.006 · Cited by 170
Sanna, S., Li, B., Mulas, A., Sidore, C., Kang, H. M., Jackson, A. U., Piras, M. G., Usala, G., Maninchedda, G., Sassu, A., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002198 · Cited by 169
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
Ai, D., Chen, C., Han, S., Ganda, A., Murphy, A. J., Haeusler, R. A., Thorp, E. B., Accili, D., Horton, J. D., & Tall, A. R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61919 · Cited by 169
Jawi, M., Frohlich, J. J., & Chan, S. (2020) · Journal of Lipids · doi:10.1155/2020/3491764 · Cited by 169
Alborn, W. E., Cao, G., Careskey, H. E., Qian, Y., Subramaniam, D. R., Davies, J., Conner, E. M., & Konrad, R. J. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.091280 · Cited by 168
Chaparro‐Riggers, J. F., Hong, L., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K. C., Casas, M. G., Boustany, L. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319764 · Cited by 168
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Moumné, L., Marie, A.-C., & Crouvezier, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020260 · Cited by 169
Linsel‐Nitschke, P., Götz, A., Erdmann, J., Brænne, I., Braund, P. S., Hengstenberg, C., Stark, K. J., Fischer, M., Schreiber, S., Mokhtari, N. E. E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002986 · Cited by 168
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166
Metadata
- Authors
- Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- Howard Hughes Medical Institute (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1264-1272
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2067539811
- Semantic Scholar
- 5cb1ad66116f87a0743739413b3b5f7f633657f8
- Cited by
- 3,181
- References
- 27
- Citations by year
- 2026: 130 · 2025: 121 · 2024: 150 · 2023: 182 · 2022: 169 · 2021: 175 · 2020: 193 · 2019: 180 · 2018: 210 · 2017: 229 · 2016: 235 · 2015: 244 · 2014: 171 · 2013: 145 · 2012: 126
- FWCI
- 104.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- W. M. Keck Foundation
- Donald W. Reynolds Foundation
- National Institutes of Health (n01hc55021-47-0-1, n01hc55020-39-0-0, n01hc55016-37-0-0, n01hc055022-024, n01hc55019-35-0-1, n01hc55018-38-0-1, N01-HC55020, N01-HC-55021, HL20948, N01-HC-55019, N01-HC-55022, N01-HC55016, N01-HC55018, N01-HC-55015, n01hc55015-48-0-1)
- National Heart, Lung, and Blood Institute (N01-HC55022, N01-HC-55018, HL-20948, N01 HC 55020, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022, N01 HC 55019, N01-HC55016, P01HL020948, N01‐HC‐55015, N01-HC55021)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, LDL cholesterol, coronary artery disease, myocardial infarction, coronary revascularization, nonsense mutation, genetic variants, LDL cholesterol lowering, cardiovascular risk, Atherosclerosis Risk in Communities Study, black and white populations
- MeSH terms
- Proprotein Convertase 9, Black or African American, Carotid Arteries, Coronary Disease, Female, Gene Frequency, Genotype, Humans, Hypolipoproteinemias, Cholesterol, LDL, Male, Middle Aged, Risk, Serine Endopeptidases, United States, Genetic Variation, Cohort Studies, Incidence, Proportional Hazards Models, Codon, Nonsense, Proprotein Convertases, Black People, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
